PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Formulae containing Shanyao (Dioscoreae rhizome) in addition to conventional treatments can benefit patients by lowering blood glucose levels [PMID:33244311].
Yam and its extracts are beneficial in controlling glycaemia in rodent models of diabetes [PMID:34521490].
Chinese yam polysaccharide (CYP) synergistically inhibited tumour growth when combined with αPD-1 monoclonal antibody in xenograft models [PMID:40267869].
Yam polysaccharides reduced colon shortening and mitigated crypt architectural distortion in mice [PMID:40498533, PMID:40360104].
Diosgenin improved CCl4-induced liver damage and reduced collagen deposition in mouse models [PMID:42066824].
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 40267869 (2025) — Chinese yam polysaccharide enhances anti-PD-1 immunotherapy in colorectal cancer through alterations in the gut microbiota and metabolites. · International journal of biological macromolecules
- 2.PMID: 38790726 (2024) — A Frontier Review of Nutraceutical Chinese Yam. · Foods (Basel, Switzerland)
- 3.PMID: 40330206 (2025) — An Update on the Nutritional and Therapeutic Potential of Dioscorea oppositifolia. · Food science & nutrition
- 4.PMID: 34521490 (2022) — Could consumption of yam (Dioscorea) or its extract be beneficial in controlling glycaemia: a systematic review. · The British journal of nutrition
- 5.PMID: 40498533 (2025) — Therapeutic impact of polysaccharide from Chinese yam (Dioscorea opposita Thunb) on DSS-induced ulcerative colitis in mice.